Mary Jo Kupst

Mary Jo Kupst

Auto-generated profile, based on publicly available information

Mary Jo Kupst

Medical College of Wisconsin

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2014 in Anxiety, stress, and coping
Verified
Journal Article
Closed access
MKMary Jo Kupst
Mary Jo Kupst
ZBZeeshan Butt
Zeeshan Butt
CSCatherine M. Stoney
Catherine M. Stoney
JGJames W. Griffith
James W. Griffith
JSJohn M. Salsman
John M. Salsman
DCDavid Cella
David Cella
Background and Objectives: The NIH Toolbox for Neurological and Behavioral Function assessment battery contains measures in the domains of cognitive function, motor function, sensory function, and emotional health. It was designed for use in epidemiological and clinical trials health-related research. Design: This paper describes the first phase of instrument development for the stress and self-efficacy subdomain of emotional health. Based on an extensive literature review and expert consultation, 127 measures were initially considered for inclusion in this subdomain, including measures of stress, self-efficacy, emotion regulation, and coping. Results: Several measures, including emotion regulation and measures of coping strategies, did not meet criteria that were a priori established for inclusion. Psychometric properties of the remaining candidate measures were evaluated using data from five independent samples (combined N = 3175). Confirmatory and exploratory factor analyses indicated the Perceived Stress Scale and the General Self-Efficacy Scale each assessed single dimensions. Conclusions: Based on their psychometric performance, these two instruments were selected for inclusion and subsequent national norming for the NIH Toolbox.

1 October 2003 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
MKMary Jo Kupst
Mary Jo Kupst
APAndrea Farkas Patenaude
Andrea Farkas Patenaude
GWGary A. Walco
Gary A. Walco
CSCheryl Sterling
Cheryl Sterling
To better understand parental perceptions of the informed consent process in pediatric oncology clinical trials, 20 parents of newly diagnosed children at two pediatric cancer centers described their perceptions in a semi-structured interview. They recalled well the diagnosis, the general treatment plan, and the statistics of survival and/or cure, but the research nature of the clinical trials, particularly randomization, was not well understood. However, despite the need to assimilate a great deal of information, time pressure to make decisions, and reportedly high levels of distress during the discussions, parents expressed general satisfaction with the informed consent discussions with their pediatric oncology providers. However, half to two thirds of parents felt there had been inadequate discussion of alternatives to the proposed treatment and of the research nature of the protocol. While further study of the informed consent process should be conducted in larger, representative samples, the findings from this pilot study suggest that a goal of future informed consent interventions should be to improve parents' understanding of the research aspects of treatment. It is critical to parents' ability to provide informed consent that they feel satisfied that they know alternatives to proposed treatment and that they understand the randomization of treatments, which is the gold standard of clinical trials in pediatric oncology.

7 April 2017 in Cancer
Verified
Journal Article
Open access
PDF file
CUChristina Ullrich
Christina Ullrich
ARAngie Mae Rodday
Angie Mae Rodday
KBKristin M. Bingen
Kristin M. Bingen
MKMary Jo Kupst
Mary Jo Kupst
SPSunita K. Patel
Sunita K. Patel
SPSusan K. Parsons
Susan K. Parsons
BACKGROUND: The experience of children undergoing hematopoietic stem cell transplantation (HSCT), including the ways in which different participants (ie, children, parents, and nurses) contribute to the overall picture of a child's experience, is poorly characterized. This study evaluated parent, child, and nurse perspectives on the experience of children during HSCT and factors contributing to interrater differences.METHODS: Participants were enrolled in a multicenter, prospective study evaluating child and parent health‐related quality of life over the year after HSCT. Children (n = 165) and their parents and nurses completed the Behavioral, Affective, and Somatic Experiences Scale (BASES) at baseline (before/during conditioning), 7 days after the stem cell infusion (day+7), and 21 days after the stem cell infusion (day+21). The BASES domains included Somatic Distress, Mood Disturbance, Cooperation, and Getting Along. Higher scores indicated more distress/impairment. Repeated measures models by domain assessed differences by raters and changes over time and identified other factors associated with raters' scores.RESULTS: Completion rates were high (≥73% across times and raters). Multivariate models revealed significant time‐rater interactions, which varied by domain. For example, parent‐rated Somatic Distress scores increased from baseline to day+7 and remained elevated at day+21 (P< .001); children's scores were lower than parents' scores across time points. Nurses' baseline scores were lower than parents' baseline scores, although by day+21 they were similar. Older child age was associated with higher Somatic Distress and Mood Disturbance scores. Worse parent emotional functioning was associated with lower scores across raters and domains except for Cooperation.CONCLUSIONS: Multirater assessments are highly feasible during HSCT. Ratings differ by several factors; considering ratings in light of such factors may deepen our understanding of the child's experience.Cancer2017;123:3159–66.©2017 American Cancer Society.

1 January 2016
Verified
Book Chapter
Closed access
PDF file
MKMary Jo Kupst
Mary Jo Kupst
APAndrea Farkas Patenaude
Andrea Farkas Patenaude

18 December 2014 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
BPBrian W. Pennarola
Brian W. Pennarola
ARAngie Mae Rodday
Angie Mae Rodday
KBKristin Bingen
Kristin Bingen
LSLisa A. Schwartz
Lisa A. Schwartz
SPSunita Patel
Sunita Patel
SPSusan K. Parsons
Susan K. Parsons

9 April 2015 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
KHKatherine E Heinze
Katherine E Heinze
ARAngie Mae Rodday
Angie Mae Rodday
MNMarie T Nolan
Marie T Nolan
KBKristin Bingen
Kristin Bingen
MKMary Jo Kupst
Mary Jo Kupst
SPSusan K Parsons
Susan K Parsons
Parents often experience stress-related complications when their child requires blood and marrow transplant (BMT). Previous studies have described the emotional toll BMT places on parents during the acute phase of care and within the context of clinical complications. In this paper we introduce the Parent Impact Scale (PARimpact), designed to capture physical and emotional challenges of the child’s health on the parent. The primary aim of this paper is to examine psychometric properties of PARimpact, and the secondary aim is to explore factors associated with PARimpact scores for further hypothesis generation. This analysis used a merged dataset of two longitudinal studies. Accompanying parents (n = 363) of children undergoing BMT were surveyed up to six times from pre-BMT baseline to one year after their child’s BMT. For this analysis, pre-BMT baseline responses to PARimpact were used to examine the factor structure with Principal Component Analysis (PCA) and Exploratory Factor Analysis (EFA). Construct validity was assessed, and multivariable regression was used to examine relationships between PARimpact and BMT clinical variables. PCA and EFA revealed a one-factor solution with acceptable item loading; Cronbach’s α was 0.83 at baseline. Hypothesized differences in known groups were detected for BMT complications with significantly higher PARimpact scores for those with vs. without each complication. In the adjusted multivariable regression models, acute graft versus host disease (b = 5.3; p = 0.03), end organ toxicity (b = 5.9; p < 0.01), and systemic infection (b = 9.1; p < 0.01) were associated with significantly higher mean PARimpact scores in the first 3 months following transplant. After the first 3 months to 1 year post BMT, systemic infection was associated with increased mean PARimpact scores (b = 19.2; p < 0.01). Initial results suggest that the PARimpact is valid and reliable. Our finding that clinical complications increase the impact of BMT on the caretaking parent indicates the need for BMT healthcare professionals to identify these events and help parents navigate the BMT course. Clinical application of the PARimpact scale should be considered to identify high-risk families and provide targeted interventions to augment care.